M3 Advisory Group’s Biogen BIIB Stock Holding History

M3 Advisory Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-885	Closed	-$205K	–	153
2024 Q2	$205K	Buy	+885	New	+$192K	0.17%	125
2024 Q1	–	Sell	-848	Closed	-$219K	–	133
2023 Q4	$219K	Buy	+848	New	+$208K	0.26%	91

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

M3 Advisory Group's BIIB Position: Q3 2024 in Review

M3 Advisory Group sold out of Biogen (BIIB) in Q3 2024, closing a stake of 885 shares — an estimated $205K sold.

M3 Advisory Group first reported a position in BIIB in Q4 2023 and held it in 2 quarters. The position peaked at $219K in Q4 2023. 916 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

M3 Advisory Group reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
M3 Advisory Group sold 885 Biogen shares in Q3 2024, an estimated $205K.
M3 Advisory Group first reported a position in Biogen in Q4 2023 and held it in 2 quarters.
M3 Advisory Group's Biogen position peaked at $219K in Q4 2023.
916 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on M3 Advisory Group's 13F filing for Q3 2024, filed 17 Oct 2024.